Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Lung Cancer

  Free Subscription


05.04.2021

2 Am J Respir Crit Care Med
1 Ann Oncol
2 Ann Surg Oncol
1 Ann Thorac Surg
9 Anticancer Res
2 BMC Cancer
3 Br J Cancer
1 Cancer Epidemiol Biomarkers Prev
2 Cancer Lett
8 Clin Lung Cancer
3 Hum Pathol
1 Int J Cancer
2 J Cancer Res Clin Oncol
12 J Thorac Oncol
2 JAMA Oncol
1 Lancet
1 Lung Cancer
2 Lung Cancer (Auckl)
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Respir Crit Care Med

  1. FORBES LM, Gu S, Badesch DB
    Surrogate Markers for Pulmonary Hypertension May Inform Prognosis in Lung Cancer.
    Am J Respir Crit Care Med. 2021 Mar 31. doi: 10.1164/rccm.202103-0740.
    PubMed        

  2. TURNER RD, Birring SS
    Neurokinin-1 Receptor Inhibition and Cough.
    Am J Respir Crit Care Med. 2021;203:672-674.
    PubMed        


    Ann Oncol

  3. BAUDIN E, Caplin M, Garcia-Carbonero R, Fazio N, et al
    Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up().
    Ann Oncol. 2021;32:439-451.
    PubMed        


    Ann Surg Oncol

  4. TSAI PC, Yeh YC, Hsu PK, Chen CK, et al
    CT-Guided Core Biopsy for Peripheral Sub-solid Pulmonary Nodules to Predict Predominant Histological and Aggressive Subtypes of Lung Adenocarcinoma.
    Ann Surg Oncol. 2020;27:4405-4412.
    PubMed         Abstract available

  5. JUNG W, Cho S, Yum S, Chung JH, et al
    Stepwise Disease Progression Model of Subsolid Lung Adenocarcinoma with Cystic Airspaces.
    Ann Surg Oncol. 2020;27:4394-4403.
    PubMed         Abstract available


    Ann Thorac Surg

  6. OLIVE JK, Zhou N, Mitchell KG, Corsini EM, et al
    Impact of Psychiatric Comorbidities on Surgical Outcomes for Non-Small Cell Lung Cancer.
    Ann Thorac Surg. 2021 Mar 24. pii: S0003-4975(21)00557.
    PubMed         Abstract available


    Anticancer Res

  7. ITO N, Masuda T, Nakashima T, Nakao S, et al
    Autoantibody Positivity Is a Risk Factor for Chemotherapy-induced Exacerbation of Interstitial Pneumonia in Lung Cancer.
    Anticancer Res. 2021;41:1497-1506.
    PubMed         Abstract available

  8. CHEN WT, Chen CH, Su HT, Yueh PF, et al
    Amentoflavone Induces Cell-cycle Arrest, Apoptosis, and Invasion Inhibition in Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2021;41:1357-1364.
    PubMed         Abstract available

  9. GRIESING S, Liao BC, Yang JC
    CD73 Is Regulated by the EGFR-ERK Signaling Pathway in Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:1231-1242.
    PubMed         Abstract available

  10. LEE HK, Noh MH, Hong SW, Kim SM, et al
    Erlotinib Activates Different Cell Death Pathways in EGFR-mutant Lung Cancer Cells Grown in 3D Versus 2D Culture Systems.
    Anticancer Res. 2021;41:1261-1269.
    PubMed         Abstract available

  11. DIMAKAKOS E, Livanios K, Vathiotis I, Gomatou G, et al
    Risk Factors for Venous Thromboembolism in Patients With Small Cell Lung Cancer.
    Anticancer Res. 2021;41:1523-1528.
    PubMed         Abstract available

  12. SATO Y, Iihara H, Kinomura M, Hirose C, et al
    Primary Prophylaxis of Febrile Neutropenia With Pegfilgrastim in Small-cell Lung Cancer Patients Receiving Amrubicin as Second-line Therapy.
    Anticancer Res. 2021;41:1615-1620.
    PubMed         Abstract available

  13. HIRASHIMA T, Noda Y, Suzuki H, Nasu S, et al
    Extracellular Water-to-total Body Water Ratio as an Objective Biomarker for Frailty in Lung Cancer Patients.
    Anticancer Res. 2021;41:1655-1662.
    PubMed         Abstract available

  14. ASANO Y, Yamamoto N, Hayashi K, Takeuchi A, et al
    Complete Response of Bone Metastasis in Non-small Cell Lung Cancer With Pembrolizumab: Two Case Reports.
    Anticancer Res. 2021;41:1693-1699.
    PubMed         Abstract available

  15. IWASHITA K, Mizuno T, Kumazawa S, Imaizumi K, et al
    Drug-induced Interstitial Lung Disease Has the Same Degree of Risk for Mortality as Old Age in Patients With Lung Cancer.
    Anticancer Res. 2021;41:1707-1711.
    PubMed         Abstract available


    BMC Cancer

  16. KIM SR, Hong JH, Sung SY, Kim YH, et al
    Efficacy of concurrent chemoradiotherapy for patients with limited-disease small-cell lung cancer: a retrospective, nationwide, population-based cohort study.
    BMC Cancer. 2021;21:340.
    PubMed         Abstract available

  17. VANTHOMME K, Rosskamp M, De Schutter H, Vandenheede H, et al
    Lung cancer incidence differences in migrant men in Belgium, 2004-2013: histology-specific analyses.
    BMC Cancer. 2021;21:328.
    PubMed         Abstract available


    Br J Cancer

  18. MACBETH F, Fallowfield DL
    Reply to 'Comment on "The myth of pulmonary metastasectomy'".
    Br J Cancer. 2020;123:1835-1836.
    PubMed        

  19. TRAN CHAU V, Liu W, Gerbe de Thore M, Meziani L, et al
    Differential therapeutic effects of PARP and ATR inhibition combined with radiotherapy in the treatment of subcutaneous versus orthotopic lung tumour models.
    Br J Cancer. 2020;123:762-771.
    PubMed         Abstract available

  20. ZELLWEGER M, Gonzalez M
    Comment on: the myth of pulmonary metastasectomy.
    Br J Cancer. 2020;123:1833-1834.
    PubMed        


    Cancer Epidemiol Biomarkers Prev

  21. BYUN J, Han Y, Ostrom QT, Edelson J, et al
    The shared genetic architectures between lung cancer and multiple polygenic phenotypes in genome-wide association studies.
    Cancer Epidemiol Biomarkers Prev. 2021 Mar 26. pii: 1055-9965.EPI-20-1635.
    PubMed         Abstract available


    Cancer Lett

  22. LIN CY, Huang KY, Lin YC, Yang SC, et al
    Vorinostat combined with brigatinib overcomes acquired resistance in EGFR-C797S-mutated lung cancer.
    Cancer Lett. 2021;508:76-91.
    PubMed         Abstract available

  23. LEE S, Hong JH, Kim JS, Yoon JS, et al
    Cancer-associated fibroblasts activated by miR-196a promote the migration and invasion of lung cancer cells.
    Cancer Lett. 2021;508:92-103.
    PubMed         Abstract available


    Clin Lung Cancer

  24. GUO HY, Lin JT, Huang HH, Gao Y, et al
    Development and Validation of a (18)F-FDG PET/CT-Based Clinical Prediction Model for Estimating Malignancy in Solid Pulmonary Nodules Based on a Population With High Prevalence of Malignancy.
    Clin Lung Cancer. 2020;21:47-55.
    PubMed         Abstract available

  25. FRANCESCHINI D, De Rose F, Cozzi S, Renna I, et al
    Volumetric Modulated Arc Therapy After Lung Sparing Surgery for Malignant Pleural Mesothelioma: A Single Institution Experience.
    Clin Lung Cancer. 2020;21:86-93.
    PubMed         Abstract available

  26. SATOH H, Miyazaki K, Kagohashi K
    Letter to the Editor Regarding "Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy".
    Clin Lung Cancer. 2021 Feb 27. pii: S1525-7304(21)00051.
    PubMed        

  27. GARON EB, Cho BC, Reinmuth N, Lee KH, et al
    Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC).
    Clin Lung Cancer. 2021 Feb 19. pii: S1525-7304(21)00033.
    PubMed         Abstract available

  28. MATTAR MS, Chang J, Benayed R, Halpenny D, et al
    Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma.
    Clin Lung Cancer. 2020;21:e25-e29.
    PubMed        

  29. TSUTSUMI H, Yoneshima Y, Ota K, Otsubo K, et al
    Multiclonality and Radiosensitivity of Granulocyte-colony Stimulating Factor-Producing Lung Adenocarcinoma Positive for an Activating EGFR Mutation.
    Clin Lung Cancer. 2020;21:e21-e24.
    PubMed        

  30. DOI H, Kuribayashi K, Kitajima K, Yamakado K, et al
    Development of a Novel Prognostic Risk Classification System for Malignant Pleural Mesothelioma.
    Clin Lung Cancer. 2020;21:66-74.
    PubMed         Abstract available

  31. CASTELLO A, Toschi L, Rossi S, Finocchiaro G, et al
    Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy.
    Clin Lung Cancer. 2020;21:28-36.
    PubMed         Abstract available


    Hum Pathol

  32. REN HZ, Cheung S, Churg A
    c-MET immunohistochemistry for differentiating malignant mesothelioma from benign mesothelial proliferations.
    Hum Pathol. 2020;105:31-36.
    PubMed         Abstract available

  33. PRABHAKARAN S, Hocking A, Kim C, Hussey M, et al
    The potential utility of GATA binding protein 3 for diagnosis of malignant pleural mesotheliomas.
    Hum Pathol. 2020;105:1-8.
    PubMed         Abstract available

  34. LAFLAMME P, Mansoori BK, Sazanova O, Orain M, et al
    Phospho-histone-H3 immunostaining for pulmonary carcinoids: impact on clinical appraisal, interobserver correlation, and diagnostic processing efficiency.
    Hum Pathol. 2020;106:74-81.
    PubMed         Abstract available


    Int J Cancer

  35. TEN HAAF K, van der Aalst CM, de Koning HJ, Kaaks R, et al
    Personalising lung cancer screening: an overview of risk-stratification opportunities and challenges.
    Int J Cancer. 2021 Mar 30. doi: 10.1002/ijc.33578.
    PubMed         Abstract available


    J Cancer Res Clin Oncol

  36. LI X, Liu L, Song X, Wang K, et al
    TEP linc-GTF2H2-1, RP3-466P17.2, and lnc-ST8SIA4-12 as novel biomarkers for lung cancer diagnosis and progression prediction.
    J Cancer Res Clin Oncol. 2021 Jan 29. pii: 10.1007/s00432-020-03502.
    PubMed         Abstract available

  37. HARA N, Ichihara E, Harada D, Inoue K, et al
    Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    J Cancer Res Clin Oncol. 2021 Mar 29. pii: 10.1007/s00432-021-03615.
    PubMed         Abstract available


    J Thorac Oncol

  38. DIMOU A, Grewe P, Sidney J, Sette A, et al
    HLA Class I Binding of Mutant EGFR Peptides in NSCLC Is Associated With Improved Survival.
    J Thorac Oncol. 2021;16:104-112.
    PubMed         Abstract available

  39. REARDON ES, Shukla V, Xi S, Gara SK, et al
    UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2021;16:89-103.
    PubMed         Abstract available

  40. SATO H, Offin M, Kubota D, Yu HA, et al
    Allele-Specific Role of ERBB2 in the Oncogenic Function of EGFR L861Q in EGFR-Mutant Lung Cancers.
    J Thorac Oncol. 2021;16:113-126.
    PubMed         Abstract available

  41. SANDS J, Tammemagi MC, Couraud S, Baldwin DR, et al
    Lung Screening Benefits and Challenges: A Review of The Data and Outline for Implementation.
    J Thorac Oncol. 2021;16:37-53.
    PubMed         Abstract available

  42. OSAROGIAGBON RU, Rami-Porta R, Tsao MS, Montuenga LM, et al
    The International Association for the Study of Lung Cancer (IASLC) Molecular Database Project: Objectives, Challenges and Opportunities.
    J Thorac Oncol. 2021 Mar 23. pii: S1556-0864(21)01781.
    PubMed        

  43. CARBONE M, Lednicky J, Xiao SY, Venditti M, et al
    Coronavirus Infectious Disease Epidemic (COVID-19): where we are, what can be done and hope for.
    J Thorac Oncol. 2021 Jan 7. pii: S1556-0864(20)31140.
    PubMed         Abstract available

  44. TRAVIS WD, Dacic S, Sholl LM, Wistuba II, et al
    Pathologic Assessment of Lung Squamous Cell Carcinoma After Neoadjuvant Immunotherapy.
    J Thorac Oncol. 2021;16:e9-e10.
    PubMed        

  45. CALLSTROM MR, de Baere T
    Response to Is Cryoablation Really Safe and Efficacious: Analyzing Results Within SOLSTICE Trial.
    J Thorac Oncol. 2021;16:e6-e7.
    PubMed        

  46. SHARMA A, Kamal VK
    Is Cryoablation Really Safe and Efficacious? Analyzing Results From the SOLSTICE Trial.
    J Thorac Oncol. 2021;16:e5.
    PubMed        

  47. BAIRD AM, Finn SP, Gray SG, Sheils O, et al
    Epigenetic Modifier UHRF1 May Be a Potential Target in Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2021;16:14-16.
    PubMed        

  48. LEE JJ, Yin G
    Principles and Reporting of Bayesian Trials.
    J Thorac Oncol. 2021;16:30-36.
    PubMed         Abstract available

  49. LUO YH, Chiu CH, Scott Kuo CH, Chou TY, et al
    Lung Cancer in Republic of China.
    J Thorac Oncol. 2021;16:519-527.
    PubMed        


    JAMA Oncol

  50. WANG J, Lu S, Yu X, Hu Y, et al
    Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2021 Apr 1. pii: 2777901. doi: 10.1001/jamaoncol.2021.0366.
    PubMed         Abstract available

  51. OSAROGIAGBON RU
    Tislelizumab-A Promising New Option for Enhancing Chemotherapy Benefit in Treatment for Advanced Squamous Cell Lung Cancer.
    JAMA Oncol. 2021 Apr 1. pii: 2777904. doi: 10.1001/jamaoncol.2021.0262.
    PubMed        


    Lancet

  52. KHO SS, Ho YF, Chan SK, Tie ST, et al
    Mediastinal melioidosis masquerading as malignancy of the lung.
    Lancet. 2021;397:e8.
    PubMed        


    Lung Cancer

  53. EVERS J, de Jaeger K, Hendriks LEL, van der Sangen M, et al
    Trends and variations in treatment of stage I-III non-small cell lung cancer from 2008 to 2018: A nationwide population-based study from the Netherlands.
    Lung Cancer. 2021;155:103-113.
    PubMed         Abstract available


    Lung Cancer (Auckl)

  54. GIUSTINI N, Bazhenova L
    Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs).
    Lung Cancer (Auckl). 2021;12:21-34.
    PubMed         Abstract available

  55. TAN AC, Loh TJ, Kwang XL, Tan GS, et al
    Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib.
    Lung Cancer (Auckl). 2021;12:11-20.
    PubMed         Abstract available


    PLoS One

  56. BERNHARDSON BM, Tishelman C, Rasmussen BH, Hajdarevic S, et al
    Sensations, symptoms, and then what? Early bodily experiences prior to diagnosis of lung cancer.
    PLoS One. 2021;16:e0249114.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: